News|Articles|November 21, 2022

In the Lab eNewsletter

  • Pharmaceutical Technology's In the Lab eNewsletter, December 2022
  • Volume 17
  • Issue 12

Element’s New Air Treatment Testing Facility Supports Indoor Space Public Health Air Quality

Element has opened a new 7500-ft3 facility that will be used to evaluate aerosolized product efficacy for reducing airborne organisms and viral particles.

In November 2022, Element Materials Technology, a global testing, inspection, and certification company, unveiled its newest bioaerosol testing facility at its Eagan, Minn., site. The facility is designed to evaluate the efficacy of aerosolized products to reduce or eliminate indoor airborne organisms and viral particles in habitable spaces (e.g., transportation, hospitals, and schools). According to a Nov. 16, 2022 company press release, the facility is one of the first and largest post-pandemic, commercial bioaerosol testing facilities.

The 7500-ft3 Eagan facility offers real-world modeling of habitable spaces, such as hospitals, schools, and other large spaces, and houses a biocontainment lab that can be used in dual or single capacity, which allows for simultaneous testing of control and treated space under the same conditions. The lab also offers various size configurations, including 107 m3 and 214 m3, among other sizes. In addition, the lab can manage multiple air-handling scenarios, including the introduction of fresh or recirculated air. It has the capacity to test biosafety level 2 organisms, including mammalian viruses.

Because the US Environmental Protection Agency (EPA) is aiming to release guidance for air treatments in 2022 or early 2023, Element has played an instrumental role in developing a standard test method for EPA-approved public health claims for air treatments, according to the company press release. Element is collaborating with regulatory, academic, and industry experts on developing these standard test methods.

“The need for bioaerosols was defined by the pandemic, and Element is pleased to bring the industry this new, much-needed capability to fulfill emerging and critical testing needs. Precise and accurate air quality testing will be critical for public health for the future,” said Elisabeth Lackner, chief scientific officer of Element, in the press release. “We are helping customers to establish purposefully designed bioaerosol R&D level protocols that provide a strong foundation for future GLP [good laboratory practice]-compliant testing.”

Source: Element Materials Technology


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.